ERAP1 and COVID-19: Moreover, the ERAP1 rs26618 TT genotype was markedly increased in the severe COVID-19 group (50%) versus 12.5% in the mild COVID-19 group (p < 0.001) and 26.3% in the non-infected controls (p = 0.0006).